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A B S T R A C T
Background: Metoprolol is the one of the most commonly used b-blockers in the treatment of ischemic
heart disease and it is extensively metabolized in the liver undergoing oxidation by CYP2D6 isoenzyme
of cytochrome P450. Gene encoding the CYP2D6 enzyme is characterized by genetic polymorphism. The
CYP2D6 oxidation polymorphism has a major impact on the effectiveness and safety of the treatment.
The aim of the study was to evaluate the relationship between plasma concentration of metoprolol and
the CYP2D6 genotype in patients with ischemic heart disease.
Methods: Fifty patients were interviewed and subsequently enrolled into the study. The patients
received metoprolol twice daily at a dose of 50 mg. The blood samples were analyzed for two major
defective alleles for CYP2D6 – CYP2D6*4 and CYP2D6*3 – by the polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) method. Metoprolol concentration in plasma was
determined by using the new and unique high-performance liquid chromatography (HPLC) method
in the author’s own modiﬁcation with Corona CAD detector (Charged Aerosol Detection).
Results: In the test group, genotypes conditioning poor oxidation (PM) occurred in 3 patients (6%), while
47 patients (94%) had genotypes coding for extensive metabolism (EM). Patients with PM genotypes had
signiﬁcantly higher plasma concentrations of metoprolol than the patients with EM genotype (mean
92.25  SD 36.78 ng/ml vs. mean 168.22  SD 5.61 ng/ml, respectively). Established relationships were
statistically signiﬁcant (NIR test, p = 0.0009).
Conclusions: This study demonstrated that the CYP2D6 genotype remains a major determinant of the
metoprolol plasma concentrations. The pharmacogenetic effect is likely to have consequences on both,
the clinical beneﬁt of metoprolol treatment and adverse drug reactions. The use of Corona CAD detector
seems to be a very good alternative method for the determination of metoprolol concentration in plasma.
 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp.
z o.o. All rights reserved.
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b-Adrenoreceptor antagonists (b-blockers) have been drugs of
ﬁrst choice in patients with stable coronary artery disease who have
no contraindications to their use. These drugs cause the reduction in
heart rate and myocardial contractility, thereby the demand of
myocardium for oxygen is decreasing. b-Blockers by prolongation of
diastole phase increase blood ﬂow through the coronary arteries and
perfusion in myocardium. The measurable effects of the b-blockers
treatment are: improvement of exercise tolerance and reduction in
the intensity and frequency of coronary pain. b-Adrenoreceptor* Corresponding author.
E-mail address: anna.wojtczak@umed.lodz.pl (A. Wojtczak).
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1734-1140/ 2014 Institute of Pharmacology, Polish Academy of Sciences. Published bantagonists are effective in reducing morbidity and mortality in
patients with ischemic heart disease [1].
The currently used b-blockers differ in their selectivity for b1-
and b2-adrenergic receptors, lipophilicity and route of elimination.
Metoprolol is one of the most commonly used b-blockers in the
treatment of ischemic heart disease. Metoprolol is a lipophilic b1-
selective blocker. This drug is well absorbed from the gastrointes-
tinal tract and undergoes extensive distribution in body tissues; it
also passes through the blood-brain barrier. The highest plasma
concentration value of metoprolol is reached approximately 2 h
after administration of a single dose. Metoprolol is extensively
metabolized (oxidation) in the liver by the CYP2D6 isoenzyme of
cytochrome P450 [2].
The gene encoding the CYP2D6 enzyme is highly polymorphic.
The CYP2D6 oxidation polymorphism has a major impact on they Elsevier Urban & Partner Sp. z o.o. All rights reserved.
Table 1
The relationship between CYP2D6 genotype and concentrations of metoprolol in the
serum of the patients with ischemic heart disease.
Genotype n (%) Metoprolol
[ng/ml]
mean  SD
Metoprolol
[ng/ml]
range
CYP2D6*1/*1 32 (64%) 85.71  36.64 10.68–143.55
CYP2D6*1/*4 13 (26%) 99.07  30.64 58.04–157.27
CYP2D6*1/*3 2 (4%) 152.65  8.73 146.48–158.83
All EM 47 (94%) 92.25  36.78 10.68–158.83
CYP2D6*4/*4 1 (2%) 165.36 –
CYP2D6*3/*4 1 (2%) 164.61 –
CYP2D6*3/*3 1 (2%) 174.69 –
All PM 3 (6%) 168.22  5.61 164.61–174.69
PM – poor metabolizers; EM – extensive metabolizers; Test NIR p = 0.0009.
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metabolism due to genetic factors can cause side effects or reduce
the therapeutic effects. Data obtained from the meta-analysis of
large groups of patients suggest that more than 40% of adverse
events were noted due to lack of dose modiﬁcation based on the
genotype of the patient [3,4].
The CYP2D6 activity ranges considerably within a population
and includes mainly extensive metabolizers (EMs) and poor
metabolizers (PMs). There is a considerable variability in the
CYP2D6 allele distribution among different ethnic groups, result-
ing in variable percentages of PMs and EMs in a given population.
The prevalence of CYP2D6 poor metabolizers is approximately 6–
10% in Caucasian populations. Many allelic variants and a series of
subvariants of the CYP2D6 gene have been reported and the
number of alleles is still growing. Among these are fully functional
alleles, alleles with reduced function and null (non-functional)
alleles, which convey a wide range of enzyme activity, from no
activity to ultrarapid metabolism of substrates. As a consequence,
drug adverse effects or lack of drug effect may occur if standard
doses are applied. The alleles *10 (100C > T), *17 (1023C > T), and
*41 (2988G > A) give rise to substrate-dependent decreased
activity. Null alleles of CYP2D6 do not encode a functional protein
and there is no detectable residual enzymatic activity. It is clear
that alleles *3 (2637delA), *4 (1934G > A), *5 (CYP2D6 deleted), *6
(1707delT), *7(2935A > C), *8 (1758G > T), *11 (883G > C), *12
(124G > A), *14 (1758G > A), *44 (2950G > C), *56 (3201C > T) and
*62 (4044C > T) have no enzyme activity. They are responsible for
the PM phenotype when present in homozygous or compound
heterozygous constellations. These alleles are of clinical signiﬁ-
cance as they often cause altered drug clearance and drug
response. Among the most important variants are CYP2D6 *3, *4,
*5, *10, *17 and *41 [5–7].
The aim of the present study was to evaluate the relationship
between plasma concentration of metoprolol and the CYP2D6
genotype in patients with ischemic heart disease by means of a
new and unique HPLC method with Corona CAD detector.
Materials and methods
Fifty patients (38 women and 12 men) were interviewed and
subsequently enrolled into the study. The age of the patients
ranged from 39 to 81 years (mean 63.5  16.3) and was similar for
both sexes. The patients received metoprolol twice a day at a dose of
50 mg.
The protocols for the study were reviewed and approved by the
Ethics Committee on Human Research at Medical University of
Lodz. Each subject agreed to sign a written informed consent.
Examination of genotype oxidation
The blood samples were analyzed for two major defective
alleles for the CYP2D6 gene – CYP2D6*4 and CYP2D6*3 – by the
polymerase chain reaction-restriction fragment length polymor-
phism (PCR-RFLP) method according to the procedure proposed
by Smith et al. [8]. DNA was arranged from leukocytes extracted
from peripheral blood. PCR ampliﬁcation was conducted in a
Mastercycler Personal thermal cycler (Eppendorf, Germany). The
obtained product of ampliﬁcation was subjected to digestion by
restriction enzymes. The restriction endonucleases BstN 1 (New
England BioLabs, USA) (CYP2D6*4) and HpaII (Invitrogen USA)
(CYP2D6*3) were used to detect the presence or absence of
mutations at position G1934A and A2637del, respectively.
Separation of the obtained digestion products was conducted
using electrophoresis in 2% agarose gel. The obtained bands were
analyzed in UV light.Determination of the metoprolol concentration
The metoprolol concentration in plasma was determined by
using the HPLC method in the author’s own modiﬁcation with UV
DAD and Corona CAD detectors (Charged Aerosol Detection). CAD
is a new and unique technique in which the eluent after passing
through the HPLC column is dissipated in the original stream of
nitrogen to remove the mobile phase.
In order to determine plasma concentrations of metoprolol in the
patients, samples of peripheral venous blood were taken at the time
of expected maximum concentrations (2–3 h after the last dose) at
steady state. Immediately after collecting, the blood samples were
centrifuged to obtain plasma. After thawing, the samples were
subjected to extraction using the method of SPE (solid phase
extraction) on the Strata-X-C 33 mm columns (Phenomenex).
Chromatographic separation of compounds was made at
temperature of 25 8C on a Hypersil GOLD column
(150 mm  4.6 mm, 5 mm) with a pre-column (4 mm  3 mm,
5 mm). The mobile phase ﬂow was 1 ml/min. Corona CAD
detection was carried out at 20 pA and a pressure of nitrogen
2.4 bar. UV detection was performed at a wavelength of 220 and
270 nm.
The linearity was demonstrated over the range 10–200 ng/ml;
the coefﬁcient of correlation (r) was 0.9991. The limit of
quantiﬁcation (LOQ) obtained during the validation was 10 ng/
ml. The precision of the method was expressed as relative standard
deviation for repeatability (RSDr) at 20%. Evaluation of the method
accuracy was determined on the basis of the recovery value of
metoprolol standard fortiﬁed samples. The analysis obtained 93%
recovery. The concentration of metoprolol in plasma was
calculated using metoprolol standard and atenolol as an internal
standard (Sigma-Aldrich, Europe). The Chromeleon v.6.70 software
was used for registration and integration of data.
Statistical analysis
The results were statistically analyzed. The age of the patients
was characterized by giving the size of the group, the arithmetic
mean and standard deviation. The relationship between the CYP2D6
genotype and the concentrations of metoprolol was calculated using
the NIR test. A p-value less than 0.05 was considered to be
statistically signiﬁcant. All statistical calculations were made using
the statistical program STATISTICA 10 (StatSoft, Inc.).
Results
Determination of metoprolol concentration in plasma was
performed in 50 patients with ischemic heart disease, including 38
women (76.0%) and 12 men (24.0%).
Among the subjects the CYP2D6*1, CYP2D6*3 and CYP2D6*4
alleles were identiﬁed using the PCR-RFLP method. It allowed the
Fig. 1. The relationship between plasma concentration of metoprolol and CYP2D6 genotype in patients with ischemic heart disease.
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(PMs) – homo- or heterozygotes with two nonfunctional alleles
and the extensive metabolisers (EMs) – wild homozygotes or
heterozygotes with a wild and a nonfunctional allele.
Only three patients (6%) were PMs with two nonfunctional
alleles. Other subjects presented EM genotypes. The distribution of
CYP2D6 genotypes is shown in Table 1.
Mean plasma concentrations of metoprolol in the patients was
96.81  SD 40.04 ng/ml and fell within the therapeutic drug
concentrations. The correlations between plasma concentration of
metoprolol and the CYP2D6 genotype of patients with ischemic heart
disease are presented in Table 1 and Fig. 1. As the data show, the
patients with PM genotypes exhibited signiﬁcantly higher plasma
concentrations of metoprolol than EMs. The established correlations
were statistically signiﬁcant (NIR test, p = 0.0009).
Discussion
b-Adrenergic receptor antagonists are one of the most widely
used medicaments in the treatment of diseases of the cardiovas-
cular system. The polymorphism of gene encoding the CYP2D6
enzyme which is responsible for the metabolism of the b-blockers
can affect the efﬁciency of pharmacological treatment. The
changes in enzyme activity caused by the CYP2D6 gene polymor-
phism may affect the pharmacokinetics, biotransformation, and of
course drug concentration. Zhou and Wood showed that the
clearance of the carvedilol R-enantiomer (+) was 66% lower among
poor metabolizers compared to EMs. The researchers also
demonstrated that in PMs the area under the curve (AUC)
increased by 138% [9].
Metoprolol is a lipophilic selective b1-adrenergic receptor
antagonist and one of the major substrates for CYP2D6. In studies,
much attention was paid to pharmacogenetic polymorphism of the
CYP2D6 gene and its important impact on the pharmacokinetics
and pharmacodynamics of metoprolol [10]. Koytchev et al. investi-
gated the inﬂuence of the CYP2D6*4 allele on the pharmacokinetics
of metoprolol. The results of this trial demonstrated a good
correlation between the CYP2D6 genotype and plasma concentra-
tion of metoprolol. The study showed also a signiﬁcant correlationbetween the decrease in heart rate and the concentrations of
metoprolol [11]. Taguchi et al. evaluated the effect of polymorphic
alleles (CYP2D6*2, CYP2D6*10, CYP2C19*2 and CYP2C19*3), age, sex,
and heart failure on the pharmacokinetic parameters of metoprolol.
The CL/F value in patients homozygous for the CYP2D6*10 allele was
64% lower than that in patients with the CYP2D6*1/*1 or *1/*2
genotype [12]. Nozawa et al. showed, that in patients routinely
treated with metoprolol, the CYP2D6 genotype signiﬁcantly affects
circadian variations of beta-adrenergic inhibition induced by
metoprolol [13].
In the present study, we investigated the effect of the CYP2D6
gene polymorphism on the concentration of metoprolol in patients
with ischemic heart disease. Several investigations demonstrated
that the CYP2D6 genotype remains a major determinant of
metoprolol plasma concentrations during therapy. Mean plasma
concentrations of metoprolol in our patients was 96.81  SD
40.04 ng/ml and fell within the therapeutic drug concentrations. Poor
metabolizers exhibited markedly higher (1.8-fold) plasma concen-
trations of metoprolol as compared to extensive metabolizers
(168.22  5.61 ng/ml vs. 92.25  36.78 ng/ml). Established correla-
tions were statistically signiﬁcant (NIR test p = 0.0009). Our results
corresponded with a recently published systematic review and meta-
analysis by Blake et al. [14]. Pooled analysis (n = 264) demonstrated
differences in peak plasma metoprolol concentration, area under the
concentration–time curve, elimination half-life, and apparent oral
clearance that were 2.3-, 4.9-, 2.3-, and 5.9-fold lower between
extensive and poor metabolizers, respectively, and 5.3-, 13-, 2.6-, and
15-fold lower between ultrarapid and poor metabolizers (all
p < 0.001), respectively. Also Rau et al. showed that the impact of
the CYP2D6 genotype on metoprolol plasma concentration persists
during long-term treatment. PMs had a 6-fold higher steady-state
concentration of metoprolol [2].
In our patients, among homozygotes with two wild alleles, the
concentration of metoprolol is in a wide range: from 10.68 to
143.55 ng/ml. This observation may explain the presence of more
than two CYP2D6 gene copies. The multiplication of gene can
contribute to ultrarapid metabolism and thus to low concentra-
tions of the drug. However, in our study, subjects were not assessed
for the presence of gene duplication.
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tions of metoprolol among the CYP2D6*1/*3 heterozygotes with
one nonfunctional allele (EMs). Similar ﬁndings were reported by
Sharp et al. In their research the median concentrations were 3.2-
fold higher in subjects with one functional allele compared with
subjects with two functional alleles [15].
On the basis of the considerable impact of the CYP2D6
polymorphism on the disposition of substrates, it has often
been suggested that PMs are more susceptible to adverse
effects of the drugs than EMs. Lennard et al. showed longer half-
life of metoprolol in poor metabolizers (7.5 h) than in extensive
metabolizers (2.8 h). Associated with drug activity decrease
in heart rate, and thus prone to undesirable bradycardia,
the symptoms were signiﬁcantly more frequent and more
strongly expressed in patients who are poor metabolisers. In
addition, metoprolol in high concentrations in plasma may lose
cardioselectivity, exposing the PM patients to side effects
characteristic of non-selective b-blockers, such as the broncho-
spasm [16].
The relationship between CYP2D6 genotype and the occur-
rence of adverse effects from metoprolol was the subject of study
by Wuttke et al. [17]. They found a statistically signiﬁcant
approximately 5-fold increased risk of adverse reactions (either
b-blocker speciﬁc, for example, symptomatic bradycardia, or
non-speciﬁc, for example nausea) in PMs (p < 0.0001). The study
included 24 patients, while 9 patients were slow metabolisers. In
our study, adverse event rates were not inﬂuenced by differences
in plasma concentration of metoprolol and the CYP2D6
genotypes.
In our study, the concentration of metoprolol was determined
by using the new and unique HPLC method in the author’s own
modiﬁcation with a Corona CAD detector (Charged Aerosol
Detection). This method has satisfactorily parameters that
guarantee repeatability and precision of results. The presented
method of determining metoprolol by means of a Corona CAD
detector may be a good alternative for well known in literature
methods based on ﬂuorescent detection.
In conclusion, the present study indicates that the plasma
concentrations of metoprolol depends on the polymorphism of
CYP2D6. Genetically determined differences in the oxidation may
thus affect the efﬁcacy and safety of treatment with metoprolol.
This knowledge should be considered in clinical practice.
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